An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
← catalyst calendarSponsored by Delcath Systems Inc. (industry) · DCTH — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
30estimated
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-06-10 | actual | When the study began enrolling |
| Primary completion | 2024-03-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2024-03-01 | estimated | The whole study's end, after follow-up |
| First posted | 2021-08-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2023-12-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Metastatic Ocular Melanoma
- Metastatic Uveal Melanoma
Intervention
- Combination product: Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS) — also filed as percutaneous hepatic perfusion, PHP, HEPZATO
Primary outcome
what the primary-completion date above is the date OFAdverse Events
measured From eligibility until death due to any cause, for up to 104 weeks
Permalink · DCTH's whole pipeline · Catalyst calendar · Every registered study · What changed